IN THE CLAIMS

Please amend the claims as follows:

Please cancel claims 1-9 and 24-48 without prejudice. Applicants reserve the right to pursue the cancelled subject matter in a continuing application.

Claims 1-9 (Cancelled).

10. (Previously Amended) A method of inhibiting the viability of cancer cells in a mammal comprising administering an effective amount of a compound of formula (I):



(I)

wherein R^1 is lower alkyl, lower alkenyl, (hydroxy)lower alkyl, lower alkynyl, phenyl, benzyl or 2-thienyl, R^2, R^3, R^4 and R^5 are the same or different and are each hydrogen or lower alkyl; each R^6 is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, n is 1-3, R^7 is hydrogen, lower alkyl or lower alkenyl, X is oxy or thio, Y is carbonyl, $(CH_2)_{1-3}$, $(CH_2)_{1-3}SO_2$ or $(CH_2)_{1-3}C(O)$, and Z is (ω-(4-pyridyl)(C_2-C_4alkoxy), (ω-((R^8)(R^9) amino)(C_2-C_4 alkoxy), wherein R^8 and R^9 are each H, (C_1-C_3)alkyl or, together with N, are a 5- or 6-membered heterocyclic ring having 1-3 N(R^8), S or nonperoxide O; an amino acid ester of (ω-(HO)(C_2-C_4))alkoxy, N(R^8)CH(R^8)CO_2H, 1'-D-glucuronyloxy, OH, (C_2-C_4)acyloxy, SO_3H, PO_4H_2, N(NO)(OH), SO_2NH_2, PO(OH)(NH_2), $OCH_2CH_2N(CH_3)_3^+$,

amino, lower alkylamino, di(lower alkyl)amino, phenylamino, or tetrazolyl; or a pharmaceutically acceptable salt thereof; to a mammal afflicted with cancer.

11. (Original) A method of inhibiting cancer comprising administering an effective amount of the composition of claim 6 to a mammal afflicted with cancer.

12. (Original) The method of claim 10 or 11 wherein the cancer is prostate cancer.

13. (Original) The method of claim 10 or 11 wherein the cancer is multiple myeloma.

14. (Original) The method of claim 10 or 11 wherein the cancer is chronic lymphocytic leukemia.

15. (Original) The method of claim 11 wherein the composition is administered orally.

16. (Original) The method of claim 15 wherein an enterically coated dosage form is administered.

17. (Original) The method of claim 11 wherein the composition is administered parenterally.

18. (Original) The method of claim 11 wherein the composition is administered in combination with a chemotherapeutic agent.

19. (Original) The method of claim 12 wherein the composition is administered in combination with a chemotherapeutic agent.

20. (Previously Amended) The method of claim 18 wherein the chemotherapeutic agent is mitoxantrone, prednisone, estramustine, melphalan, vinblastine or a combination thereof.

21. (Previously Amended) The method of claim 19 wherein the chemotherapeutic agent is an anti-androgen.

22. The method of claim 21 wherein the anti-androgen is bicafutamide, nilutamide, flutamide, cycloproterone acetate or a combination thereof.

23. The method of claim 21 wherein the anti-androgen is leuprolide acetate, goserelin acetate or a combination thereof.

Claims 24-48 (Cancelled).